Rifampicin

利福平

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameRifampicin
Drug Alias Name抗生素利福平Rifampicine立复霉素RifampicinumRifampicina +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBacterial DNA-directed RNA polymerase inhibitors
TargetsBacterial DNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHypercalciuria +[19] 
Global Approved IndicationsTuberculosis, PulmonaryTuberculosisLeprosy +[5] 
Approved Indications in ChinaTuberculosisLeprosy
Original Approved Country/TerritoryUnited States
Original Approved Date1971/05/21
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesCanadian Institutes Of Health Research (Cihr)C.H. Boehringer Sohn Ag & Co. KgRadboud University Medical Center +[21] 
Inactive CompaniesSanofi-Aventis U.S. LlcUniversity Of North Carolina At Chapel HillVanderbilt University +[5] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHypercalciuria +[15] 
Inactive IndicationsMultiple System AtrophyCarcinoma, Non-Small-Cell LungAsymptomatic Infections +[4] 

Other Information

ATC CodeJ04AB02
Related LinksWikipediaDrugBankKEGG